Insmed Inc (INSM)

[vrtl1999]

Bob,

I may be reading the situation wrong but I feel that the risk to the patent litigation is not as risky as say before FDA approval with full orphan status. My feeling is that the FDA has deemed iPlex somewhat different than Increlex. It will be interesting to see the review of approval proccess by the FDA. I think it will be telling in as much as where the FDA felt the merits for approval lay. Soon the FDA should release the review proccess on the MCM portion of the NDA and there I think will be revealed the crux to the patent issue. I'm not saying that TRCA will drop the case but we'll (learned persons in law)be able to handicap our chances.


regards,